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ABSTRACT
Aims To examine the impact of two national tobacco control interventions in the past decade on (dispensed) pre-
scriptions of stop-smoking medication. Design Ecological study with interrupted time–series analyses of quarterly
data points of three nation-wide representative databases. Setting The Netherlands 2001–2012, with the introduc-
tion of the guideline for smoking cessation care for general practitioners (GP) in 2007 and full insurance coverage for
smoking cessation treatment in 2011. Participants GPs, pharmacists and people in the general population aged 15
years and older. Measurements Time–series plots were inspected visually and segmented regression analyses were
performed to estimate the change in level and slope of (dispensed) prescriptions of stop-smoking medication and
smoking prevalence in the years preceding and after the tobacco control interventions. Findings No measurable
effects of the GP guideline on (dispensed) prescriptions were observed. Shortly after the start of health insurance
coverage, an estimated increase in primary care prescriptions of 6.3 per 1000 smokers [95% confidence interval
(CI) = 2.9–9.8; P = 0.001] and 17.3 dispensed items per 1000 smokers (95% CI = 12.5–22.0; P < 0.000) was accom-
panied by a sudden drop in smoking prevalence of 2.9% (95% CI = 4.6–1.1; P = 0.002) in the first quarter of 2011.
Immediately after the coverage abolition, smoking prevalence increased by 1.2% (95% CI = 0.5–2.8; P = 0.156)
and dispensed prescription rates decreased with 21.6 per 1000 smokers (95% CI = 26.0–17.2; P < 0.000).
Conclusions Full health insurance coverage for smoking cessation treatment in the Netherlands was accompanied by
a significant increase in the number of (dispensed) prescriptions of stop-smoking medication and a decrease in smoking
prevalence.
Keywords Drug prescriptions, health policy, primary health care, smoking cessation, tobacco use cessation
products.
Correspondence to: Marjolein E. A. Verbiest, Leiden University Medical Centre, Department Public Health and Primary Care, PO Box 9600, 2300 RC
Leiden, the Netherlands. E-mail: m.e.a.verbiest@lumc.nl
Submitted 19 December 2012; initial review completed 7 February 2013; final version accepted 25 June 2013
INTRODUCTION
In the past decade, cigarette consumption has declined in
various high- and middle-income countries [1]. However,
about 25% of the Dutch adult population still smokes [2].
As a result, in the Netherlands, the attributive risk of
smoking-related mortality is estimated at 21%, which is
relatively high compared to 16% in Europe and 12%
world-wide [3,4]. Consequently, 13% of the Dutch
disease burden and an annual €2 billion in health-care
costs are attributed to the use of tobacco [4,5].
Therefore, in the last decade multiple national tobacco
control interventions have been implemented [6,7].
The Dutch government initiated several policies
aimed at reducing exposure to environmental tobacco
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advertisement (November 2002) and the sale of toba-
cco to minors (January 2003) were implemented, and
legislation was introduced for smoke-free work-places
(January 2004) and public places (April 2006 and July
2008). In addition, national guidelines for smoking
cessation support in health care were developed and
implemented. Moreover, in the year 2011, full health
insurance coverage for evidence-based pharmacotherapy
in combination with behavioural counselling was
implemented.
These tobacco control interventions are likely to
reduce smoking initiation, increase the number of quit
attempts and/or use of effective treatments and therefore
reduce smoking prevalence [8–15]. For example, in the
Netherlands, smoking prevalence decreased from 30.1%
in 2001 to 25.9% in 2012 [2]. However, the impact of
national tobacco control interventions on primary care
prescriptions of stop-smoking medication is not yet clear.
GPs are more likely to deliver successful smoking ces-
sation treatment when they use a systematic approach
and when structural barriers (e.g. lack of financial
reimbursement) are alleviated [16,17]. Therefore, we
examined the impact of two national tobacco control
interventions on prescriptions of stop-smoking medica-
tion in general practice that were likely to have directly
prompted GPs to support smokers to quit. These two
interventions are the guideline for smoking cessation
care introduced in general practice and the full health
insurance coverage period of stop-smoking treatment.
METHODS
Design
To explore the hypotheses, we used an ecological study
design in which the unit of analysis was the population
rather than the individual. The main advantage of this
type of study is the presence of available data which
enabled a relatively fast and inexpensive study. However,
the results cannot be extrapolated to the individual level
and no confounder data were available. Moreover, infer-
ences regarding causality need to be made with caution,
taking into account other explanations for changes in
outcomes. Nevertheless, this type of study is useful to
generate new hypotheses based on the results.
National tobacco control interventions
We assessed the impact of potentially high-impact
national tobacco control interventions on prescriptions of
stop-smoking medication in general practice, i.e. (i) the
introduction of the GP guideline for smoking cessation
care and (ii) full health insurance coverage of evidence-
based pharmaceuticals and behavioural treatment for
smoking cessation.
Implementation of the first Dutch guideline ‘Treat-
ment of Tobacco Dependence’ started in 2004, accom-
panied by campaigns in which physicians and other
health-care providers were informed about the guideline
and were provided with additional insight into the addic-
tive character of smoking [18]. This implementation
period resulted in the first version of a guideline for treat-
ment of tobacco use in general practice, developed by the
Dutch College of General Practitioners in June 2007 [19].
This guideline recommends enquiring actively about a
patient’s motivation for stopping smoking. When a patient
smokes more than 10 cigarettes/day and is motivated
to quit, the first choice recommendation is to prescribe
nicotine replacement therapy (NRT) in combination with
behavioural treatment. If requested specifically by the
patient, or in the case of relapse after NRT, the antidepres-
sant smoking cessation agents bupropion and nortriptyl-
ine are recommended. In December 2006 varenicline was
introduced in the Netherlands and (after an evaluation
period) was incorporated into the general practitioner
(GP) guideline in March 2011 [20].
In January 2011, the Dutch government introduced
full health insurance coverage for evidence-based
smoking cessation programmes using pharmacotherapy
in combination with behavioural counselling. Govern-
mental changes, a shift of focus of the Ministry of Health
on people’s autonomy regarding life-style choices, and
overall cutting in budget, led to the cancellation of full
health insurance coverage after only 1 year. As a result,
only behavioural support and not pharmacological
support for smoking cessation was reimbursed during the
year 2012.
We analysed the effects of both policies within the
same regression model, which allowed us to quantify the
effects of one policy taking into account the effect of
the other policy.
Data extraction
For a full overview of the number of primary care pre-
scriptions of stop-smoking pharmaceuticals in the past
decade we used two nation-wide representative databases
of (i) prescribed medication in general practice and (ii)
prescriptions dispensed in out-patient pharmacies. The
term ‘prescription’ refers to an order of the GP for the
pharmacist to dispense and the patient to take the medi-
cation. The act of dispensing is defined as providing a
patient with their labelled medication. In the Netherlands
all stop-smoking medications are prescription drugs, with
the exception of NRT, which is also available over the
counter.
At quarterly intervals, we extracted data on prescrip-
tions and dispensed items of stop-smoking medication in
general practices and pharmacies. Data on nortriptyline
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were excluded because this pharmaceutical is also used
for various other indications. Finally, to explore the
impact of the tobacco control interventions on smoking
prevalence a third database was used (see Data on
smoking prevalence below).
The privacy regulation of the study was registered at
the Dutch Data Protection Authority. According to
current Dutch legislation, neither informed consent nor
approval is required from a medical ethics committee for
observational studies using anonymized data records
[21].
Data on stop-smoking medication prescribed in
primary care
The number of quarterly prescribed stop-smoking medi-
cations in general practice were derived from the Nether-
lands Information Network of Primary Care (LINH) in
the period 2001–2011. Data were retrieved from elec-
tronic medical patient records, kept in a representative
sample of 84 general practices with approximately
350 000 listed patients. The characteristics of the study
population (GPs and patients) are comparable with the
general Dutch population in terms of age and gender
[22]. We selected prescriptions of NRT, varenicline and
bupropion in the period 2001–2011 and calculated pre-
scription rates per 1000 smokers. These rates were calcu-
lated by dividing the absolute number of primary care
prescriptions by the number of smokers, multiplied by
1000. The number of smokers was based on the total
population [23] and smoking prevalence [24]. In this
database it was not possible to differentiate between pre-
scriptions of bupropion as an anti-depressant or for
smoking cessation.
Data on stop-smoking medication dispensed by pharmacies
For prescriptions of stop-smoking medication dispensed
in out-patient pharmacies, we used quarterly data of the
Dutch Foundation for Pharmaceutical Statistics (SFK) in
the period 2001–2012. The SFK gathers data from a rep-
resentative panel of 95% of Dutch community pharma-
cies. Data were extrapolated to nation-wide figures. We
selected dispensations of NRT, varenicline and bupropion
in the period 2001–2012 and calculated dispensed rates
per 1000 smokers.
Data on smoking prevalence
We used quarterly data from the Dutch Continuous
Survey of Smoking Habits (DCSSH) from 2001 to 2012
for smoking prevalence. The DCSSH assesses smoking
behaviour of the Dutch adult population (15 years and
older). The DCSSH has been part of the CASI omnibus
(Computer-Assisted Self-Interviewing) of TNS NIPO from
2001 to 2008. From 2009 onwards, the DCSSH has been
performing an ad-hoc internet survey in which a repre-
sentative sample of about 350 subjects is selected from
a database of 200 000 respondents every week. Until
2008, the data from the DCSSH were weighted on the
basis of respondents’ gender, age and education level, the
province in which they lived and their family and com-
munity size. Since January 2009, the data have also been
weighted on the basis of respondents’ socio-economic
status. Smoking prevalence was assessed by asking par-
ticipants ‘Do you (ever) smoke?’.
Statistical methods
We drew and visually inspected time–series plots to detect
marked changes in the number of (dispensed) prescrip-
tions and smoking prevalence in the past decade. Inter-
rupted time–series analyses (SPSS version 20.0) were
used to evaluate the impact of the national tobacco
control interventions on (dispensed) prescriptions of
stop-smoking medications and smoking prevalence [25].
The advantages of these analyses are the fact that they
allowed us to assess whether or not the interventions
changed the outcomes immediately as well as over a
period of time, taking into account pre-existing trends in
the data [25–27]. Prior studies have shown that seg-
mented regression analysis is a suitable method for ana-
lysing interrupted time–series data in order to assess the
impact of extraneous events on smoking-related out-
comes [25,28–31]. We examined the following linear
regression equation:
Y B B B Bt t t= + × + × +
×
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Time (in quarters) was included as a continuous
predictor. Intervention indicated the introduction of
the GP guideline, and the introduction and abolition of
health insurance coverage of stop-smoking treatment;
pre-intervention time-points were coded 0 and post-
intervention time-points were coded 1. Time after inter-
vention was coded 0 up to the last time-point before
the intervention, and was coded sequentially from 1
thereafter.
In the model, Yt represents the outcome variable at
time t (the number of (dispensed) prescriptions per 1000
smokers or smoking prevalence). B0 estimates the base-
line level/intercept of the outcome at time-point zero; B1
estimates the quarterly change in outcome prior to the
interventions; B2 (introduction GP-guideline), B4 (intro-
duction insurance coverage) and B5 (abolition insurance
coverage) estimates the change in level immediately after
the interventions; and B3 estimates the change in slope
after the introduction of the GP-guideline compared with
the slope before the intervention. We assessed both full
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and parsimonious models into which we incorporated all
parameters regardless of their significance and only sig-
nificant covariates, respectively.
We did not assess the impact of the GP guideline intro-
duction on the number of (dispensed) prescriptions of
varenicline because this pharmaceutical was introduced
in the Netherlands around the same time as the GP
guideline (December 2006). Furthermore, we only
assessed the immediate effect of the introduction and
abolition of the insurance coverage in (dispensed)
prescriptions and smoking prevalence, as we lacked
sufficient time-points to estimate a change in trend.
Because time is a predictor in segmented regression
analyses it is likely that consecutive observations are cor-
related (called ‘autocorrelation’). As regression analy-
sis assumes independence between observation and
autocorrelation can over- or underestimate significance,
we examined autocorrelation by visually inspecting
residual plots. Autocorrelation was judged to be present
if there were statistically significant spikes in the
correlogram. In addition, the Durbin–Watson statistic
was used to test serial autocorrelation; based on the
number of observations and regressors in the model we
determined an upper and lower bound and tested the null
hypothesis of zero autocorrelation in the data [32]. We
found first-order autocorrelation in the time–series of the
total prescription rate, prescription rate of NVM and of
the number of (dispensed) prescription of bupropion and
varenicline. These time–series were differenced by sub-
tracting the value of an earlier observation from the
value of a later observation in order to control for
autocorrelation [25,27]. The regression models were
re-checked after time–series were differenced in order to
confirm that autocorrelation was accounted for.
RESULTS
Figure 1 shows the time–series plots of primary care pre-
scriptions of stop-smoking medication and dispensed
items in pharmacies in the past decade. It highlights
the introduction of the smoking cessation guideline in
general practice and the period of the full health insur-
ance coverage of smoking cessation treatment. Both
time–series were relatively low in the period 2001–2006,
but show a small increase after 2007. Next, both time–
series increased steeply in 2011, especially in the first and
last quarters. Thereafter, dispensed prescriptions in phar-
macies show a decrease in 2012. Overall, the number of
stop-smoking medication prescribed in general practices
is lower than dispensed in pharmacies. This can probably
be explained by other clinical specialists also prescribing
these pharmaceuticals. Further explanations are that
GPs sometimes prescribe multiple doses of stop-smoking
medications at the same time, and pharmacists some-
times dispense the labelled medication at multiple
moments to be able to check for possible side effects [33].
Figure 2 shows the number of primary care prescrip-
tions and dispensed items of NRT, varenicline and
bupropion. Visual inspection points out that, between
2001 and 2008, the number of primary care prescrip-
tions of NRT increased in the first quarter of every year,
which can be defined as seasonality in the time–series. In
this period, the prescription rates of NRT show little
change, with a single small increase in 2008. Both time–
series of NRT show a steep increase in 2011, especially in
the first and last quarters.
After the introduction of varenicline in December
2006, visual inspection of Fig. 2 shows that both pre-
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Figure 1 Smoking prevalence and the number of primary care prescriptions and dispensed prescriptions of stop-smoking medication per
1000 smokers in the period 2001–2012
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Figure 2 The number of primary care prescriptions and dispensed prescriptions of nicotine replacement therapy, varenicline and bupropion
per 1000 smokers in the period 2001–2012
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increased rapidly, particularly in the first and last quar-
ters of 2011. Next, dispensed items of varenicline show a
steep decrease in 2012.
With regard to bupropion, we observed a discrepancy
between primary care prescriptions and dispensed items
from 2007 (Fig. 2). At that time, bupropion was regis-
tered in the Netherlands as an antidepressant in addition
to stop-smoking medication [34]. The observed discrep-
ancy can be explained by the fact that the primary care
prescriptions in this study represent the total number of
prescriptions for both depression and quit smoking and
the dispensed items represent only stop-smoking medica-
tion. Both prescriptions and dispensed items of bupropion
show a single slight increase in 2004. Subsequently,
primary care prescriptions of bupropion increase in 2011
and the number of dispensed items show a slight decrease
in 2012.
GP guideline
When accounting for the effect of the introduction of the
health insurance coverage, there was no statistically sig-
nificant immediate (B2) and long-term (B3) effect of the
introduction of the GP guideline on the number of
primary care prescriptions and dispensed items (Table 1).
Health insurance coverage
According to the segmented regression analysis, the
total number of stop-smoking medication prescribed in
general practices and dispensed in pharmacies showed a
significant increase in 2011, the year in which smoking
cessation treatment was reimbursed (Table 1). In the first
quarter of 2011, prescriptions and dispensed items
increased by 6.3 per 1000 smokers [95% confidence
interval (CI) = 2.9–9.8; P = 0.001] and 17.3 per 1000
smokers (95% CI = 12.5–22.0; P < 0.000), respectively
(Table 1). This change also occurred in the number of
primary care prescriptions and dispensed items of NRT
and varenicline (Table 1). Subsequently, a significant
decrease in the number of dispensed items of stop-
smoking medication was established of 21.6 items per
1000 smokers (95% CI = 26.0 to −17.2; P < 0.000) in
the first quarter of 2012, immediately after the abolition
of the coverage. This effect also occurred in the number of
dispensed items of varenicline and NRT.
Smoking prevalence
Visual inspection of Fig. 1 shows a steady overall decline
in smoking prevalence in the period 2001–2012, with a
more prominent decrease in 2004, 2007 and 2011.
Thereafter, smoking prevalence shows a marked increase
in 2012. Segmented regression analyses confirmed a
significant decrease in the first quarter of 2011, immedi-
ately after the introduction of the health insurance cov-
erage (Table 1).
DISCUSSION
In the past decade, the number of primary care prescrip-
tions of stop-smoking medication in general practices
and dispensed items in pharmacies increased. We found a
significant change in (dispensed) prescriptions following
full health insurance coverage of stop-smoking support
in the year 2011. Moreover, our data suggest a positive
impact of this tobacco control policy on smoking preva-
lence. We did not find measurable effects of the introduc-
tion of a guideline for smoking cessation care in general
practice on prescription rates.
Current results compared to previous research
These results complement other Dutch reports indicating
an upward trend in the use of pharmacological aids for
smoking cessation in recent years [35]. Nevertheless,
relatively few stop-smoking prescriptions are suggested
actively by GPs and guidelines for cessation support are
often implemented suboptimally in general practice
[15,36,37]. Moreover, these guidelines also comprise
behavioural cessation support, which we did not address
in our study, which may explain why we did not find
effects of the introduction of the GP guideline introduc-
tion on prescription rates.
Regarding our findings related to the effect of full
health insurance coverage on prescription rates and
smoking prevalence, the latest research also shows a
strong association between this policy and a more than
10-fold increase in telephone counselling for smoking
cessation [38]. Moreover, a recent review of 11
randomized controlled trials from four countries found a
positive effect of full health insurance coverage on the use
of smoking cessation treatment [17].
Strengths and weaknesses
A strength of our study is that three large nation-wide
representative databases were used with regard to pre-
scriptions in general practice, dispensed items in pharma-
cies and smoking prevalence. With regard to the SFK
database, in 2011 an unknown and possibly substantial
part of Dutch health insurance companies covered dis-
pensed prescriptions of stop-smoking medications only
of specific (online) pharmacies; therefore, the precise
number of dispensed items was unknown in this year.
This implies that these data might underestimate the
actual situation and that the impact of health insurance
coverage might be even larger. Another strength of the
study is the fact that in the Dutch health-care system
6 Marjolein E. A. Verbiest et al.
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almost all non-institutionalized Dutch citizens are regis-
tered with a general practice, which resulted in data with
strong external validity.
Regarding the analyses, we assessed the impact of
tobacco control interventions with quarterly data points,
which enabled us to detect subtle temporary effects in the
period prior to or immediately after the interventions.
Additionally, we included the most recent available data
in order to analyse changes following the abolition of the
health insurance coverage.
However, some limitations of the study have to be
mentioned. First, it was not possible to differentiate
between bupropion prescriptions for treating depression
and those used as a quit-smoking aid in general practice.
Furthermore, we did not include data regarding NRT dis-
tributed over the counter. Because the estimated mean
costs of NRT are €2.57 per day [39], this may have been
an incentive for patients to obtain a prescription from
the GP during the period that smoking cessation aids
were reimbursed. For this reason, it is possible that the
reported large increase in the number of (dispensed) pre-
scriptions of NRT in the period 2011–2012 is caused
partially by the fact that over-the-counter distribution of
these aids are not included into the analyses in the pre-
intervention period.
With regard to the segmented regression analyses,
when assessing the impact of an intervention on time–
series the impact of extraneous events on the observed
changes in the series must be taken into account [28]. In
the past decade, multiple tobacco control policies have
been implemented in the Netherlands which might have
had an (indirect) effect on the number of prescriptions;
for example, tax increases and smoke-free legislation in
the work-place (2004) and other public areas (2008).
However, in 2011 no other tobacco control measures
were introduced in the Netherlands. Although caution is
required in assuming causal relations, it seems likely that
the increase in (dispensed) prescriptions and decrease in
smoking prevalence in 2011 can be attributed to the
introduction of health insurance coverage. This assump-
tion is supported by the fact that we visually detected a
marked increase in smoking prevalence and statistically
confirmed a decrease in dispensed items immediately
after the abolition of the coverage.
CONCLUSION AND PRACTICAL
IMPLICATIONS
The results of this study suggest that health insurance
coverage for smoking cessation treatment prompt GPs to
prescribe evidence-based pharmaceuticals for smoking
cessation and have positive effects on smoking preva-
lence. Therefore, these results are a relevant addition to
the existing evidence demonstrating the importance of
tobacco control policies in effective tackling of the
tobacco epidemic [9–14,28,40,41].
We argue that policy makers and the tobacco control
community consider this evidence in developing future
tobacco control policy. Given the limitations of our
study, we recommend the replication of population-based
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